Prevention And Management Of Chemotherapy-Induced Peripheral Neuropathy In Survivors Of Adult Cancers
Publication Date: July 14, 2020
Key Points
Key Points
- Chemotherapy-induced neuropathy (CIPN) is a serious clinical problem caused by a substantial number of cytotoxic drugs, including taxanes, platinums, vinca alkaloids, epothilones, eribulin, and bortezomib.
- No agents are recommended for the prevention of CIPN.
- Duloxetine is the only agent that has appropriate evidence to support its use, but the amount of benefit from duloxetine is limited.
- Therefore, prevention and minimizing risk are the primary objectives.
- Because patients with CIPNBecause patients with CIPNBecause patients with CIPN can have balance troubles and a higher chance of falling, it is reasonable to consider physical and/or occupational therapy approaches for patients with such CIPN-related disabilities.
Prevention
...Prevention...
...Pr...
...1.1Clinicians should assess the risks a...
...ion 1.2Clinicians should NOT offer, and sho...
...ion 1.3Outside the context of a clinical trial, no...
...ommendation 1.4Clinicians should NOT offer t...
Treatment
Treatme...
...Treatment...
...mendation 2.1Clinicians should assess,...
...Treatment of...
Recommendation 3.1For cancer patients exp...
...ecommendation 3.2Outside the context of...
Summary of Recommendations
...RecommendationsHaving trouble viewing table?...